Physician profile
Michaeline Bailey
NPI 1447890298
$5,575.70
in general payments reported to CMS, 2019-2025
26 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,450 · 2023: $634 · 2024: $1,871 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,336.63 | 2022-2023 | Venaseal |
| Astrazeneca Pharmaceuticals Lp | $818.01 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $675.57 | 2023-2025 | |
| Lilly USA, LLC | $373.30 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $302.45 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $292.84 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.37 | 2023-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $233.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $220.66 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $132.55 | 2022 | |
| Shield Therapeutics INC | $123.26 | 2023-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $113.04 | 2024-2025 | Rexulti |
| Pfizer INC. | $96.34 | 2023-2025 | |
| Exact Sciences Corporation | $85.09 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ascensia Diabetes Care US INC. | $84.99 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $61.54 | 2025 | Daxxify |
| Ibsa Pharma INC. | $52.36 | 2024-2025 | Licart, Tirosint, Flector |
| Mylan Specialty L.P. | $44.51 | 2023-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.72 | 2025 | Xifaxan |
| Edwards Lifesciences Corporation | $39.43 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $34.89 | 2023-2024 | |
| Lundbeck LLC | $33.22 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $25.60 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $22.41 | 2024 | Voquezna |
| Dexcom, INC. | $20.95 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $18.56 | 2024 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaeline Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.